Decheng Capital Global Life Sciences Fund IV, L.P.
CG Oncology, Inc. Common stock · 10% Owner
Decheng Capital Global Life Sciences Fund IV, L.P. holds a significant position as a 10% Owner of CG Oncology, Inc., focusing on investments in the healthcare sector. Recent disclosures reflect purchase activity, with a notable investment of $7.6 million reported on January 31, 2024. This profile compiles SEC Form 4 filings, detailing the fund's engagement with CG Oncology, Inc. and its strategic investment approach.
Latest Trades
| Company | Value | Action | Price | Last Price |
|---|---|---|---|---|
| $8M400k shares | BuyJan 29, 2024 | $19.00 | $69.50 |